Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
Kobe Univ. Aims to Become APEC “Center of Excellence”; Could Promote Stronger Japanese Role in Regulatory Harmonization
Kobe University aims to obtain certification as an APEC Training Center of Excellence for Regulatory Science (CoE), an initiative through which APEC certifies institutions in the region to train personnel at regulatory authorities. The certification is an initiative of APEC’s…
To read the full story
Related Article
- Kobe Univ. Received Pilot Certification as APEC Training Center of Excellence
September 20, 2019
- New “Center of Excellence” to Be Set Up in US to Train Regulators from APEC Region, Promote Multiregional Clinical Trials
September 5, 2018
- PMDA Certified as APEC’s Training Center of Excellence for Regulatory Science
March 6, 2017
ACADEMIA
- NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
- Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
- Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
- Real-World Study Backs Lecanemab Safety, 90% Stay on Treatment
March 25, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…